Business Context and Reporting Period
GRI Bio, Inc. is referenced as the target in Vallon Pharmaceuticals, Inc.’s Form 8-K filed March 31, 2023, reporting an event occurring March 31, 2023. Under the December 13, 2022 merger agreement, Vallon Merger Sub, Inc. would merge with and into GRI, with GRI surviving as a wholly owned subsidiary of Vallon.
The filing provides supplemental disclosures to Vallon’s March 8, 2023 prospectus following seven demands from purported Vallon stockholders alleging that the prospectus, registration statement, or preliminary versions omitted or misstated material information concerning the merger.
Financial Metrics and Capital Resources
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics for GRI or Vallon.
Material Changes Versus the Prior Comparable Period
- The filing reports no operating or financial-period comparison.
- Vallon disclosed that seven stockholder demands had been received concerning merger disclosures. As of March 31, 2023, Vallon was not aware of any commenced action relating to the merger.
- Vallon stated that it believed the demands were without merit but voluntarily supplemented the prospectus to reduce litigation, delay, expense, distraction, and transaction risk.
Guidance, Outlook, Risks, and Unusual Items
- The demands included reservations of rights; one included a draft complaint alleging violations of Sections 14(a) and 20(a) of the Securities Exchange Act. Proposed relief included delaying or enjoining the merger until additional disclosures were made, damages, and attorneys’ fees.
- Vallon denied that the supplemental disclosures were legally required or material and stated it might not announce further developments unless new or different material allegations arise.
- Companies that discussed potential transactions with Vallon and Ladenburg executed customary nondisclosure agreements containing standstill provisions effective until the merger agreement was executed. The provisions did not preclude topping bids.
- Ladenburg had not provided services to Altium Growth Fund, LP during the two years before its January 26, 2023 fairness opinion and did not receive, or expect to receive, compensation for such services.
- The combined company’s board was agreed to comprise one Vallon designee and four GRI designees, with David Baker as the Vallon designee.
- GRI was to select management of the combined company. Leanne Kelly entered into an employment agreement with GRI on February 20, 2023 to continue as chief financial officer upon merger closing.
- The filing cautions that completion of the merger and the conclusions regarding the demands involve risks and uncertainties. Investors are directed to Vallon’s SEC filings for additional risk factors.
Most Important Facts to Verify
- Whether the merger was ultimately completed, including the closing date and final ownership and capitalization structure.
- Whether any complaint or other legal proceeding was filed in connection with the seven demands and any resulting costs, settlement, injunction, or delay.
- The complete supplemental disclosures and underlying merger terms in the March 8, 2023 prospectus and Form S-4 registration statement.
- The final composition of the combined company’s board and management, including Ms. Kelly’s employment terms.
- Current financial statements, liquidity, debt, operating results, and risk disclosures, which are not provided in this Form 8-K.